A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.

Once again, our signature emerged as a potent predictor, as evidenced by a highly significant difference in patient responses following immunotherapy ( p < .0001), as depicted in Figure 17(B) .

also in 132,142 other papers